These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. Carr BR; Marshburn PB; Weatherall PT; Bradshaw KD; Breslau NA; Byrd W; Roark M; Steinkampf MP J Clin Endocrinol Metab; 1993 May; 76(5):1217-23. PubMed ID: 8496313 [TBL] [Abstract][Full Text] [Related]
23. [Research on the relationship between estrogen receptor, progesterone receptor, cell proliferation associated antigen in uterine leiomyoma and nuclear body density of myoma, serum reproductive hormone concentrations]. Wu J; Cheng Y Zhonghua Fu Chan Ke Za Zhi; 1995 Oct; 30(10):603-7. PubMed ID: 8745507 [TBL] [Abstract][Full Text] [Related]
24. Decreased prolactin secretion by explant cultures of fibroids from women treated with a gonadotropin-releasing hormone agonist. Rein MS; Friedman AJ; Heffner LJ J Clin Endocrinol Metab; 1990 Jun; 70(6):1554-8. PubMed ID: 2112150 [TBL] [Abstract][Full Text] [Related]
25. A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue. Filicori M; Hall DA; Loughlin JS; Rivier J; Vale W; Crowley WF Am J Obstet Gynecol; 1983 Nov; 147(6):726-7. PubMed ID: 6356927 [No Abstract] [Full Text] [Related]
26. [Study on the local estrogen biosynthesis in human uterine leiomyoma]. Urabe M; Yamamoto T; Naito K; Kitawaki J; Honjo H; Okada H Nihon Sanka Fujinka Gakkai Zasshi; 1990 Sep; 42(9):1229-36. PubMed ID: 2212823 [TBL] [Abstract][Full Text] [Related]
27. Medical treatment of uterine myoma with long-acting gonadotropin-releasing hormone agonist prior to myomectomy. Liu CH; Lin YS; Lin CC; Tzeng CC; Chou CY J Formos Med Assoc; 1993 Jun; 92(6):536-9. PubMed ID: 8106041 [TBL] [Abstract][Full Text] [Related]
28. [Effects of mifepristone on estrogen and progestin receptors in human uterine leiomyoma]. Wang H; Jin J Zhonghua Fu Chan Ke Za Zhi; 2000 Feb; 35(2):79-81. PubMed ID: 11809103 [TBL] [Abstract][Full Text] [Related]
29. Expression of basic fibroblast growth factor (bFGF), FGF receptor 1 and FGF receptor 2 in uterine leiomyomas and myometrium during the menstrual cycle, after menopause and GnRHa treatment. Wu X; Blanck A; Olovsson M; Möller B; Lindblom B Acta Obstet Gynecol Scand; 2001 Jun; 80(6):497-504. PubMed ID: 11380284 [TBL] [Abstract][Full Text] [Related]
30. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma. Waibel-Treber S; Minne HW; Scharla SH; Bremen T; Ziegler R; Leyendecker G Hum Reprod; 1989 May; 4(4):384-8. PubMed ID: 2526152 [TBL] [Abstract][Full Text] [Related]
31. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657 [TBL] [Abstract][Full Text] [Related]
32. Treatment of uterine fibroids with agonist analogs of gonadotropin-releasing hormone. Kessel B; Liu J; Mortola J; Berga S; Yen SS Fertil Steril; 1988 Mar; 49(3):538-41. PubMed ID: 3277869 [TBL] [Abstract][Full Text] [Related]
33. D-Trp-6-luteinizing hormone-releasing hormone microcapsules in the treatment of uterine leiomyomas. Golan A; Bukovsky I; Schneider D; Ron-el R; Herman A; Caspi E Fertil Steril; 1989 Sep; 52(3):406-11. PubMed ID: 2528476 [TBL] [Abstract][Full Text] [Related]
35. Estrogen and progesterone receptor content of enucleated uterine myomata after luteinizing hormone-releasing hormone. Analogue depot therapy. Cirkel U; Ochs H; Roehl A; Schneider HP Acta Obstet Gynecol Scand; 1994 Apr; 73(4):328-32. PubMed ID: 8160541 [TBL] [Abstract][Full Text] [Related]
36. Combined oestrogen-progestin treatment of vaginal haemorrhage following gonadotrophin-releasing hormone agonist therapy of uterine myomas. Friedman AJ Hum Reprod; 1993 Apr; 8(4):540-2. PubMed ID: 8501181 [TBL] [Abstract][Full Text] [Related]
37. Short-term and long-term results of resectoscopic myomectomy with and without pretreatment with GnRH analogs in premenopausal women. Campo S; Campo V; Gambadauro P Acta Obstet Gynecol Scand; 2005 Aug; 84(8):756-60. PubMed ID: 16026401 [TBL] [Abstract][Full Text] [Related]
39. The effects of add-back therapy with tibolone on myoma uteri. Göçmen A; Kara IH; Karaca M Clin Exp Obstet Gynecol; 2002; 29(3):222-4. PubMed ID: 12519049 [TBL] [Abstract][Full Text] [Related]
40. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist. Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]